- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.34 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x YBO: (2P)-2-{5-(cyclopropylmethyl)-3-(4-fluorophenyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid
YBO.2: 21 residues within 4Å:- Chain A: R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.1, EDO.3
15 PLIP interactions:15 interactions with chain A- Hydrophobic interactions: A:R.106, A:L.109, A:N.138, A:P.139, A:A.238, A:Y.239, A:I.242
- Hydrogen bonds: A:N.138, A:D.141, A:I.142, A:E.192, A:E.192, A:T.248
- Salt bridges: A:R.169, A:H.193
YBO.15: 20 residues within 4Å:- Chain B: R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.14, EDO.21
13 PLIP interactions:13 interactions with chain B- Hydrophobic interactions: B:L.109, B:N.138, B:A.238, B:Y.239
- Hydrogen bonds: B:N.138, B:D.141, B:I.142, B:E.192, B:E.192, B:T.248, B:T.248
- Salt bridges: B:R.169, B:H.193
YBO.24: 21 residues within 4Å:- Chain C: R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, D.195, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.23, EDO.25
14 PLIP interactions:14 interactions with chain C- Hydrophobic interactions: C:R.106, C:L.109, C:N.138, C:P.139, C:A.238, C:Y.239, C:I.242
- Hydrogen bonds: C:N.138, C:D.141, C:D.141, C:I.142, C:E.192
- Salt bridges: C:R.169, C:H.193
YBO.37: 20 residues within 4Å:- Chain D: R.106, L.109, V.110, N.138, P.139, V.140, D.141, I.142, L.165, R.169, E.192, H.193, G.194, A.238, Y.239, I.242, T.248, L.323
- Ligands: NAI.36, EDO.43
12 PLIP interactions:12 interactions with chain D- Hydrophobic interactions: D:L.109, D:N.138, D:A.238, D:Y.239
- Hydrogen bonds: D:N.138, D:D.141, D:D.141, D:I.142, D:E.192, D:T.248
- Salt bridges: D:R.169, D:H.193
- 34 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
EDO.3: 4 residues within 4Å:- Chain A: R.106, Y.239, I.242
- Ligands: YBO.2
Ligand excluded by PLIPEDO.4: 4 residues within 4Å:- Chain A: M.63, Q.66
- Chain C: Y.172, E.176
Ligand excluded by PLIPEDO.5: 5 residues within 4Å:- Chain A: A.87, N.88, K.126, Y.127, P.129
Ligand excluded by PLIPEDO.6: 5 residues within 4Å:- Chain A: G.208, V.209, S.210
- Chain B: S.202
- Ligands: EDO.9
Ligand excluded by PLIPEDO.7: 8 residues within 4Å:- Chain A: A.30, M.33, A.34, Y.247, S.249, W.250
- Chain C: W.250
- Ligands: EDO.29
Ligand excluded by PLIPEDO.8: 6 residues within 4Å:- Chain A: N.21, K.90, K.132, M.264, Q.297
- Chain D: N.21
Ligand excluded by PLIPEDO.9: 12 residues within 4Å:- Chain A: S.202, G.203, N.205, G.208, S.210
- Chain B: S.202, G.203, M.204, N.205, G.208, S.210
- Ligands: EDO.6
Ligand excluded by PLIPEDO.10: 7 residues within 4Å:- Chain A: Q.66, P.75, K.76, I.77, V.78
- Chain C: Y.172, E.176
Ligand excluded by PLIPEDO.11: 5 residues within 4Å:- Chain A: I.283, K.284, D.285, A.320, D.321
Ligand excluded by PLIPEDO.12: 4 residues within 4Å:- Chain A: L.280, Y.281, K.305, V.306
Ligand excluded by PLIPEDO.13: 1 residues within 4Å:- Chain A: K.149
Ligand excluded by PLIPEDO.17: 7 residues within 4Å:- Chain B: A.30, M.33, A.34, Y.247, S.249, W.250
- Chain D: W.250
Ligand excluded by PLIPEDO.18: 7 residues within 4Å:- Chain B: L.40, M.41, D.43, F.71, L.72, R.73
- Chain D: K.42
Ligand excluded by PLIPEDO.19: 7 residues within 4Å:- Chain B: N.164, S.167, A.168, R.171, P.272
- Chain D: L.70, F.71
Ligand excluded by PLIPEDO.20: 4 residues within 4Å:- Chain B: Y.10, N.11, L.12
- Chain C: K.155
Ligand excluded by PLIPEDO.21: 3 residues within 4Å:- Chain B: R.106, Y.239
- Ligands: YBO.15
Ligand excluded by PLIPEDO.22: 7 residues within 4Å:- Chain B: Q.66, S.69, P.75, K.76, I.77
- Chain D: Y.172, E.176
Ligand excluded by PLIPEDO.25: 4 residues within 4Å:- Chain C: R.106, Y.239, I.242
- Ligands: YBO.24
Ligand excluded by PLIPEDO.26: 4 residues within 4Å:- Chain A: Y.172, E.176
- Chain C: M.63, Q.66
Ligand excluded by PLIPEDO.27: 5 residues within 4Å:- Chain C: A.87, N.88, K.126, Y.127, P.129
Ligand excluded by PLIPEDO.28: 5 residues within 4Å:- Chain C: G.208, V.209, S.210
- Chain D: S.202
- Ligands: EDO.31
Ligand excluded by PLIPEDO.29: 8 residues within 4Å:- Chain A: W.250
- Chain C: A.30, M.33, A.34, Y.247, S.249, W.250
- Ligands: EDO.7
Ligand excluded by PLIPEDO.30: 6 residues within 4Å:- Chain B: N.21
- Chain C: N.21, K.90, K.132, M.264, Q.297
Ligand excluded by PLIPEDO.31: 12 residues within 4Å:- Chain C: S.202, G.203, N.205, G.208, S.210
- Chain D: S.202, G.203, M.204, N.205, G.208, S.210
- Ligands: EDO.28
Ligand excluded by PLIPEDO.32: 7 residues within 4Å:- Chain A: Y.172, E.176
- Chain C: Q.66, P.75, K.76, I.77, V.78
Ligand excluded by PLIPEDO.33: 5 residues within 4Å:- Chain C: I.283, K.284, D.285, A.320, D.321
Ligand excluded by PLIPEDO.34: 4 residues within 4Å:- Chain C: L.280, Y.281, K.305, V.306
Ligand excluded by PLIPEDO.35: 1 residues within 4Å:- Chain C: K.149
Ligand excluded by PLIPEDO.39: 7 residues within 4Å:- Chain B: W.250
- Chain D: A.30, M.33, A.34, Y.247, S.249, W.250
Ligand excluded by PLIPEDO.40: 7 residues within 4Å:- Chain B: K.42
- Chain D: L.40, M.41, D.43, F.71, L.72, R.73
Ligand excluded by PLIPEDO.41: 7 residues within 4Å:- Chain B: L.70, F.71
- Chain D: N.164, S.167, A.168, R.171, P.272
Ligand excluded by PLIPEDO.42: 4 residues within 4Å:- Chain A: K.155
- Chain D: Y.10, N.11, L.12
Ligand excluded by PLIPEDO.43: 3 residues within 4Å:- Chain D: R.106, Y.239
- Ligands: YBO.37
Ligand excluded by PLIPEDO.44: 7 residues within 4Å:- Chain B: Y.172, E.176
- Chain D: Q.66, S.69, P.75, K.76, I.77
Ligand excluded by PLIP- 2 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Lowther, W.T. et al., Human Lactate Dehydrogenase A in complex with inhibitor CHK-336. To Be Published
- Release Date
- 2024-01-24
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
B
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.34 Å
- Oligo State
- homo-tetramer
- Ligands
- 4 x NAI: 1,4-DIHYDRONICOTINAMIDE ADENINE DINUCLEOTIDE(Non-covalent)
- 4 x YBO: (2P)-2-{5-(cyclopropylmethyl)-3-(4-fluorophenyl)-4-[(3-fluoro-4-sulfamoylphenyl)methyl]-1H-pyrazol-1-yl}-1,3-thiazole-4-carboxylic acid
- 34 x EDO: 1,2-ETHANEDIOL(Non-functional Binders)
- 2 x PEG: DI(HYDROXYETHYL)ETHER(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Lowther, W.T. et al., Human Lactate Dehydrogenase A in complex with inhibitor CHK-336. To Be Published
- Release Date
- 2024-01-24
- Peptides
- L-lactate dehydrogenase A chain: ABCD
- SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AB
BC
AD
B